NCT00106171 is a Phase 4 clinical trial of Highly active antiretroviral therapy (HAART) in HIV Infections, sponsored by Johns Hopkins Bloomberg School of Public Health.

Who is sponsoring NCT00106171?

NCT00106171 is sponsored by Johns Hopkins Bloomberg School of Public Health.

What drugs are being tested in NCT00106171?

Interventions in NCT00106171: Highly active antiretroviral therapy (HAART).

What condition does NCT00106171 study?

NCT00106171 studies HIV Infections.

Is NCT00106171 still recruiting?

NCT00106171 is currently completed. Last updated 22 August 2023.

Are results published for NCT00106171?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-08-22 · How we verify

NCT00106171

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized Trial of HAART in Acute/Early HIV Infection

Completed Phase 4 Results posted Last updated 22 August 2023

What this trial tests

Phase 4 trial testing Highly active antiretroviral therapy (HAART) in HIV Infections in 113 participants. Completed in 1 May 2012.

Timeline

1 May 2005

Primary endpoint
1 May 2012

1 May 2012

Quick facts

Lead sponsor	Johns Hopkins Bloomberg School of Public Health
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	113
Start date	1 May 2005
Primary completion	1 May 2012
Estimated completion	1 May 2012
Sites	5 locations across United States, Canada

Drugs / interventions tested

Highly active antiretroviral therapy (HAART) — full drug profile →

Conditions studied

HIV Infections — all drugs for HIV Infections →

Sponsor

Johns Hopkins Bloomberg School of Public Health

Who can join

18 and older, any sex, with HIV Infections. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Total Treatment-free Time to Initiation of Permanent HAART
Time frame: Through study completion, an average of 18 months
All HAART-free time from initial infection with HIV to initiation of permanent HAART

Sponsor's own description

It is not known if anti-HIV treatment for recently infected patients improves long-term patient prognosis. The purpose of this study is to determine if a one year course of anti-HIV medications slows progression of HIV disease in adults recently infected with HIV. Study hypothesis: A one-year course of HAART administered during acute or early seroconversion may slow the progression of HIV infection.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

HIV-1 Gag evolution in recently infected human leukocyte antigen-B*57 patients with low-level viremia.
Durand CM, O'Connell KA, Apuzzo LG, Langan SJ, et al · · 2010 · cited 10× · PMID 20671542 · DOI 10.1097/qad.0b013e32833d8a38
HIV-1 evolution following transmission to an HLA-B*5801-positive patient.
O'Connell KA, Xu J, Durbin AP, Apuzzo LG, et al · · 2009 · cited 10× · PMID 19909081 · DOI 10.1086/648377
A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection.
Margolick JB, Apuzzo L, Singer J, Wong H, et al · · 2015 · cited 1× · PMID 26600459 · DOI 10.1371/journal.pone.0143259

Verify or expand the search:

Other trials of Highly active antiretroviral therapy (HAART)

Trials testing the same drug.

NCT00955968 — IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women · Phase 4 · completed

Other recruiting trials for HIV Infections

Currently open trials in the same condition.

NCT07225530 — Implementation of Screen, Treat, and Triage for Women Living With HIV in La Romana (iSTAR) · NA · recruiting
NCT07202546 — A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) · Phase 2 · recruiting
NCT06694753 — Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall · Phase 1 · recruiting
NCT07235852 — Pilot Testing Into the Feasibility of the Developed Cognitive Behavioral Therapy Intervention · NA · recruiting
NCT06665646 — Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Ad · Phase 1 · recruiting

Other Johns Hopkins Bloomberg School of Public Health trials

Trials by the same sponsor.

NCT07458230 — Efficacy of Integrating Next Generation Sequencing for Treatment of Surgical Site Infection After Fracture Fixation: · Phase 3 · not yet recruiting
NCT07227558 — Improving Information Sharing Between Family Caregivers and Home Care Aides · NA · recruiting
NCT07536126 — Testing Non-Nutrition Menu Labels on Food Selections · NA · not yet recruiting
NCT06426004 — Addressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland · NA · not yet recruiting
NCT07344142 — Improving Digital Wellbeing in Saudi Adolescents · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00106171 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johns Hopkins Bloomberg School of Public Health
Last refreshed: 22 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00106171.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing